The Abu Dhabi Public Health Centre (ADPHC) has signed a two-year Memorandum of Understanding (MoU) with Novartis Middle East FZE to combat non-communicable diseases in the emirate. The collaboration aims to enhance public health outcomes through improved awareness, prevention, and disease management—particularly for cardiovascular diseases, diabetes, and chronic kidney disease.
This public-private initiative focuses on three strategic pillars:
1. Disease Awareness:
The partners will co-develop digital and traditional campaigns to highlight risk factors and early symptoms. The goal is to drive proactive behaviours such as regular health screenings and early intervention, particularly among adults.
2. Disease Prevention:
The collaboration will roll out targeted screening efforts to detect at-risk individuals early. Initiatives will support the primary prevention of adult-onset cardiovascular diseases, diabetes, and chronic kidney disease.
3. Best Practice Sharing in Disease Management:
ADPHC and Novartis will collaborate on implementing global best practices across the patient journey. From early screening to ongoing management, the aim is to improve care models and system-wide health performance.
To ensure effective implementation, the MoU establishes a joint taskforce. Both parties will appoint leads to oversee execution, define deliverables, monitor feasibility, and track progress using agreed-upon key performance indicators (KPIs).
This collaboration reinforces Abu Dhabi’s ongoing commitment to addressing non-communicable diseases through innovation, partnerships, and community engagement.
